Reduced Natriuretic Effect of Atrial Natriuretic Peptide in Nephrotic Syndrome: A Possible Role of Decreased Cyclic Guanosine Monophosphate

To evaluate therapeutic and side effects, atrial natriuretic peptide (ANP) was administered as a pharmacological bolus dose (2 µg/kg body weight) to 7 patients with nephrotic syndrome and to 13 age- a